Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2012 Jun 16;48:2–58. [Article in Spanish] doi: 10.1016/S0300-2896(12)70035-2

Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC)

Clinical Practice Guideline for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC)

Grupo de Trabajo de GesEPOC, Task Force of GesEPOC
PMCID: PMC7131261  PMID: 23116901

The content is available as a PDF (1.8 MB).

Bibliografía

  • 1.Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86–98. doi: 10.1016/j.arbres.2011.10.007. [DOI] [PubMed] [Google Scholar]
  • 2.Soriano J.B., Zielinski J., Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009;374:721–732. doi: 10.1016/S0140-6736(09)61290-3. [DOI] [PubMed] [Google Scholar]
  • 3.Estrategia en EPOC del Sistema Nacional de Salud . Ministerio de Sanidad y Política Social; Madrid: 2009. Plan de Calidad para el Sistema Nacional de Salud. [Google Scholar]
  • 4.Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Disponible en: http://www.goldcopd.org.
  • 5.Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L. Guía clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Asociación Latinoamericana del Tórax (ALAT) Arch Bronconeumol. 2008;44:271–281. [Google Scholar]
  • 6.Grupo de trabajo de la guía de práctica clínica sobre atención integral al paciente con enfermedad pulmonar obstructiva crónica (EPOC). Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Sociedad Española de Medicina de Familia (semFYC); 2010.
  • 7.Han M.K., Agustí A., Calverley P.M., Celli B.R., Criner G., Curtis J.L. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010;182:598–604. doi: 10.1164/rccm.200912-1843CC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch Bronconeumol. 2009;45(Supl 5):27–34. doi: 10.1016/S0300-2896(09)72952-7. [DOI] [PubMed] [Google Scholar]
  • 9.Grupo de trabajo GESEPOC Hacia un nuevo enfoque en el tratamiento de la EPOC. La Guía Española de la EPOC (GESEPOC) Arch Bronconeumol. 2011;47:379–381. doi: 10.1016/j.arbres.2011.05.008. [DOI] [PubMed] [Google Scholar]
  • 10.Anderson D., MacNee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obst Pulm Dis. 2009;4:321–335. doi: 10.2147/copd.s2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Manual Metodológico para la elaboración de guías de práctica clínica del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo; 2007. Disponible en: http://www.guiasalud.es/emanuales/elaboracion/documentos/Manual%20metodologico%20%20Elaboracion%20GPC%20en%20el%20SNS.pdf.
  • 12.Guyatt G., Oxman A.D., Akl E.A., Kunz R., Vist G., Brozek J. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394. doi: 10.1016/j.jclinepi.2010.04.026. [DOI] [PubMed] [Google Scholar]
  • 13.Marzo Castillejo M., Montaño Barrientos A. El sistema GRADE para la toma de decisiones clínicas y la elaboración de recomendaciones y guías de práctica clínica. Aten Primaria. 2007;39:457–460. doi: 10.1157/13109491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Guyatt G.H., Oxman A.D., Kunz R., Woodcock J., Brozek J., Helfand M. GRADE guidelines: 8. Rating the quality of evidenced indirectness. J Clin Epidemiol. 2011;64:1303–1310. doi: 10.1016/j.jclinepi.2011.04.014. [DOI] [PubMed] [Google Scholar]
  • 15.Bousquet J., Kiley J., Bateman E.D., Viegi G., Cruz A.A., Khaltaev N. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J. 2010;36:995–1001. doi: 10.1183/09031936.00012610. [DOI] [PubMed] [Google Scholar]
  • 16.Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M. International variation in the prevalence of COPD (the BOLD study): a populationbased prevalence study. Lancet. 2007;370:741–750. doi: 10.1016/S0140-6736(07)61377-4. [DOI] [PubMed] [Google Scholar]
  • 17.Halbert R.J., Natoli J.L., Gano A., Badamgarav E., Buist A.S., Mannino D.M. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–532. doi: 10.1183/09031936.06.00124605. [DOI] [PubMed] [Google Scholar]
  • 18.Atsou K., Chouaid C., Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7. doi: 10.1186/1741-7015-9-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sobradillo-Peña V.S., Miravitlles M., Gabriel R., Jiménez- Ruiz C.A., Villasante C., Masa J.F. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981–989. doi: 10.1378/chest.118.4.981. [DOI] [PubMed] [Google Scholar]
  • 20.Miravitlles M., Ferrer M., Pont A., Viejo J.L., Masa J.F., Gabriel R. Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respir Med. 2005;99:985–995. doi: 10.1016/j.rmed.2005.01.012. [DOI] [PubMed] [Google Scholar]
  • 21.Miravitlles M., Soriano J.B., García-Río F., Muñoz L., Duran-Taulería E., Sánchez G. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–868. doi: 10.1136/thx.2009.115725. [DOI] [PubMed] [Google Scholar]
  • 22.Soriano J.B., Ancochea J., Miravitlles M., García-Río F., Duran E., Muñoz L. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007. Eur Respir J. 2010;36:758–765. doi: 10.1183/09031936.00138409. [DOI] [PubMed] [Google Scholar]
  • 23.WHO. World health statistics 2008. Disponible en: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. 2010.
  • 24.Regidor E, Gutiérrez-Fisac JL, Alfaro M. Patrón de mortalidad en España, 2008. Madrid: Ministerio de Sanidad, Política Social e Igualdad, 2011. Disponible en: http://www.msc.es/ca/estadEstudios/estadisticas/estadisticas/estMinisterio/mortalidad/docs/Patrones_de_Mortalidad_en_Espana_2008.pdf.
  • 25.Raziel: Mortalidad por todas las causas. Área de Análisis Epidemiológico y Situación de Salud. Disponible en: http://193.146.50.130/raziel.php.
  • 26.Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. Disponible en: http://www.msc.es/estadEstudios/estadisticas/cmbd.htm.
  • 27.Ministerio de Sanidad y Política Social. Plan de Calidad para el Sistema Nacional de Salud. Estrategia en EPOC del Sistema Nacional de Salud. Sanidad 2009. Ministerio de Sanidad y Política Social. Disponible en: http://www.msc.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf.
  • 28.Miravitlles M., Murio C., Guerrero T., Gisbert R., on behalf of the DAFNE study group Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784–791. doi: 10.1378/chest.123.3.784. [DOI] [PubMed] [Google Scholar]
  • 29.Soler-Cataluña J.J., Calle M., Cosio B.G., Marín J.M., Monso E., Alfageme I. Estándares de calidad asistencial en la EPOC. Arch Bronconeumol. 2009;45:361–362. doi: 10.1016/j.arbres.2008.05.008. [DOI] [PubMed] [Google Scholar]
  • 30.Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304. [DOI] [PubMed] [Google Scholar]
  • 31.Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:332–338. doi: 10.1164/rccm.200712-1869OC. [DOI] [PubMed] [Google Scholar]
  • 32.Patel B.D., Coxson H.O., Pillai S.G., Agustí A.G.N., Calverley P.M.A., Donner C.F. Airway wall thickening and emphysema show independente familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:500–505. doi: 10.1164/rccm.200801-059OC. [DOI] [PubMed] [Google Scholar]
  • 33.Martínez-García F., Soler-Cataluña J.J., Donat Y., Catalán P., Agramunt M., Ballestin V. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest. 2011;140:1130–1137. doi: 10.1378/chest.10-1758. [DOI] [PubMed] [Google Scholar]
  • 34.Garcia-Aymerich J., Gómez F.P., Benet M., Farrero E., Basagaña X., Gayete A. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) phenotypes. Thorax. 2011;66:430–437. doi: 10.1136/thx.2010.154484. [DOI] [PubMed] [Google Scholar]
  • 35.Vidal R., Blanco I., Casas F., Jardí R., Miravitlles M. Comité del Registro Nacional de Pacientes con Déficit de Alfa-1-antitripsina. Normativa SEPAR: Diagnóstico y tratamiento del déficit de alfa-1-antitripsina. Arch Bronconeumol. 2006;42:645–659. doi: 10.1016/s1579-2129(07)60007-x. [DOI] [PubMed] [Google Scholar]
  • 36.Hurst J.R., Vestbo J., Anzeto A., Locantore N., Müllerova H., Tal-Singer R. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi: 10.1056/NEJMoa0909883. [DOI] [PubMed] [Google Scholar]
  • 37.Soler Cataluña J.J., Martínez García M.A., Catalán Serra P. The frequent exacerbator. A new phenotype in COPD? Hot Topics Respir Med. 2011;6:7–12. [Google Scholar]
  • 38.Quint J.K., Donaldson G.C., Hurst J.R., Goldring J.J.P., Seemungal T.R., Wedzicha J.A. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37:501–507. doi: 10.1183/09031936.00035909. [DOI] [PubMed] [Google Scholar]
  • 39.Bafadhel M., McKenna S., Terry S., Mistry V., Reid C., Haldar P. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi: 10.1164/rccm.201104-0597OC. [DOI] [PubMed] [Google Scholar]
  • 40.Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–735. doi: 10.1136/thx.2008.108027. [DOI] [PubMed] [Google Scholar]
  • 41.Contoli M., Baraldo S., Marku B., Casolari P., Marwick J.A., Turato G. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: a 5-year follow-up. J Allergy Cin Immunol. 2010;125:830–837. doi: 10.1016/j.jaci.2010.01.003. [DOI] [PubMed] [Google Scholar]
  • 42.Boulet L.P., Lemiere C., Archambault F. Smoking and asthma: clinical and radiological features, lung function, and airway inflammation. Chest. 2006;129:661–668. doi: 10.1378/chest.129.3.661. [DOI] [PubMed] [Google Scholar]
  • 43.O’Donnell D.E., Aaron S., Bourbeau J., Hernandez P., Marciniuk D.D., Balter M. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2007 update. Can Respir J. 2007;14(Suppl):B:5B–B:B32. doi: 10.1155/2007/830570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nagai A., Aizawa H., Aoshiba K., Asano K., Hirata K., Ichinose M. 3rd. Medical Review Co. Ltd; Tokyo (Japan): 2009. Guidelines for the diagnosis and treatment of COPD. The Japanese Respiratory Society. [Google Scholar]
  • 45.De Marco R., Accordini S., Cerveri I., Corsico A., Antó J.M., Künzli N. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175:32–39. doi: 10.1164/rccm.200603-381OC. [DOI] [PubMed] [Google Scholar]
  • 46.Miravitlles M. The overlap síndrome between asthma and COPD: implications for management. Hot Topics Respir Med. 2011;16:15–20. [Google Scholar]
  • 47.Hardin M., Silverman E.K., Barr R.G., Hansel N.H., Schroeder J.D., Make B.J. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127. doi: 10.1186/1465-9921-12-127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Soriano J.B., Davis K.J., Coleman B., Visick G., Mannino D., Pride N.B. The proportional Venn diagram of obstructive lung disease. Chest. 2003;124:474–481. doi: 10.1378/chest.124.2.474. [DOI] [PubMed] [Google Scholar]
  • 49.American Thoracic Society Chronic bronchitis, asthma, and pulmonary emphysema, a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962;85:762–768. [Google Scholar]
  • 50.Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333–1338. doi: 10.1183/09031936.95.08081333. [DOI] [PubMed] [Google Scholar]
  • 51.Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med. 2011;105:1118–1128. doi: 10.1016/j.rmed.2011.02.003. [DOI] [PubMed] [Google Scholar]
  • 52.Montes de Oca M., Halbert R.J., López M.V., Pérez-Padilla R., Tálamo C., Moreno D. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012 doi: 10.1183/09031936.00141611. (on line) [DOI] [PubMed] [Google Scholar]
  • 53.Kim V., Han M.K., Vance G.B., Make B.J., Newel J.D., Hokanson J.E. The chronic bronchitic phenotype of COPD. An analysis of the COPDGene study. Chest. 2011;140:626–633. doi: 10.1378/chest.10-2948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Patel I.S., Vlahos I., Wilkinson T.M.A., Lloyd-Owen S.J., Donaldson G.C., Wilks M. Bronchiectasis, exacerbation índices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:400–407. doi: 10.1164/rccm.200305-648OC. [DOI] [PubMed] [Google Scholar]
  • 55.Casanova C., Cote C., De Torres J.P., Aguirre-Jaime A., Marín J.M., Pinto-Plata V. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591–597. doi: 10.1164/rccm.200407-867OC. [DOI] [PubMed] [Google Scholar]
  • 56.Grydeland T.B., Thorsen E., Dirksen A., Jensen R., Coxson H.O., Pillai S.G. Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO. Respir Med. 2011;105:343–351. doi: 10.1016/j.rmed.2010.10.018. [DOI] [PubMed] [Google Scholar]
  • 57.Han M.K., Kazerooni E.A., Lynch D.A., Liu L.X., Murray S., Curtis J.L. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261:274–282. doi: 10.1148/radiol.11110173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Nishimura M., Makita H., Nagai K., Konno S., Nasuhara Y., Hasegawa M. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52. doi: 10.1164/rccm.201106-0992OC. [DOI] [PubMed] [Google Scholar]
  • 59.Oswald N.C., Medvei V.C. Chronic bronchitis: the effect of cigarette-smoking. Lancet. 1955;269:843–844. doi: 10.1016/s0140-6736(55)93480-2. [DOI] [PubMed] [Google Scholar]
  • 60.Anderson D., Ferris B.G., Jr. Role of tobacco smoking in the causation of chronic respiratory disease. N Engl J Med. 1962;267:787–794. doi: 10.1056/NEJM196210182671601. [DOI] [PubMed] [Google Scholar]
  • 61.Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648. doi: 10.1136/bmj.1.6077.1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Kohansal R., Martinez-Camblor P., Agusti A., Buist A.S., Mannino D.M., Soriano J.B. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham off spring cohort. Am J Respir Crit Care Med. 2009;180:3–10. doi: 10.1164/rccm.200901-0047OC. [DOI] [PubMed] [Google Scholar]
  • 63.Lokke A., Lange P., Scharling H., Fabricius P., Vestbo J. Developing COPD: a 25 year follows up study of the general population. Thorax. 2006;61:935–939. doi: 10.1136/thx.2006.062802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Encuesta de salud de España. Disponible en: http://www.msc.es.
  • 65.Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in nonsmokers. Lancet. 2009;374:733–743. doi: 10.1016/S0140-6736(09)61303-9. [DOI] [PubMed] [Google Scholar]
  • 66.Jaakkola M.S., Jaakkola J.J. Effects of environmental tobacco smoke on the respiratory health of adults. Scand J Work Environ Health. 2002;28(Suppl 2):52–70. [PubMed] [Google Scholar]
  • 67.Larsson M.L., Loit H.M., Meren M., Põlluste J., Magnusson A., Larsson K. Passive smoking and respiratory symptoms in the FinEsS Study. Eur Respir J. 2003;21:672–676. doi: 10.1183/09031936.03.00033702. [DOI] [PubMed] [Google Scholar]
  • 68.Yin P., Jiang C.O., Cheng K.K., Lam T.H., Lam K.H., Miller M.R. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007;370:751–757. doi: 10.1016/S0140-6736(07)61378-6. [DOI] [PubMed] [Google Scholar]
  • 69.Ho S.Y., Lam T.H., Chung S.F., Lam T.P. Cross-sectional and prospective associations between passive smoking and respiratory symptoms at the workplace. Ann Epidemiol. 2007;17:126–131. doi: 10.1016/j.annepidem.2006.06.010. [DOI] [PubMed] [Google Scholar]
  • 70.González Barcala F.J., Takkouche B., Valdés L., Temes E., Leis R., Cabanas R. Tabaquismo parental y función pulmonar en niños y adolescentes. Arch Bronconeumol. 2007;43:81–85. doi: 10.1016/s1579-2129(07)60028-7. [DOI] [PubMed] [Google Scholar]
  • 71.Torres-Duque C., Maldonado D., Pérez-Padilla R., Ezzati M., Viegi G. Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass. Exposure biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc. 2008;5:577. doi: 10.1513/pats.200707-100RP. [DOI] [PubMed] [Google Scholar]
  • 72.Hu G., Zhou Y., Tian J., Yao W., Li J., Li B. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest. 2010;138:20–31. doi: 10.1378/chest.08-2114. [DOI] [PubMed] [Google Scholar]
  • 73.Kurmi O.P., Semple S., Simkhada P., Smith W.C., Ayres J.G. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax. 2010;65:221–228. doi: 10.1136/thx.2009.124644. [DOI] [PubMed] [Google Scholar]
  • 74.Po J.Y., FitzGerald J.M., Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011;66:232–239. doi: 10.1136/thx.2010.147884. [DOI] [PubMed] [Google Scholar]
  • 75.Orozco-Levi M., García-Aymerich J., Villar J., Ramírez-Sarmiento A., Antó J.M., Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:542–546. doi: 10.1183/09031936.06.00052705. [DOI] [PubMed] [Google Scholar]
  • 76.Eisner M.D., Anthonisen N., Coultas D., Kuenzli N., Pérez-Padilla R., Postma D. Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693–718. doi: 10.1164/rccm.200811-1757ST. [DOI] [PubMed] [Google Scholar]
  • 77.Arbex M.A., De Souza Conceição G.M., Cendon S.P., Arbex F.F., Lopes A.C., Moysés E.P. Urban air pollution and COPD-related emergency room visits. J Epidemiol Community Health. 2009;63:777–783. doi: 10.1136/jech.2008.078360. [DOI] [PubMed] [Google Scholar]
  • 78.Andersen Z.J., Hvidberg M., Jensen S.S., Ketzel M., Loft S., Sørensen M. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med. 2011;183:455–461. doi: 10.1164/rccm.201006-0937OC. [DOI] [PubMed] [Google Scholar]
  • 79.EURAD [acceso 18 de mayo de 2011]. Disponible en: http://www.eurad.unikoeln.de/.
  • 80.Rushton L. Occupational causes of chronic obstructive pulmonary disease. Rev Environ Health. 2007;22:195–212. doi: 10.1515/reveh.2007.22.3.195. [DOI] [PubMed] [Google Scholar]
  • 81.Rodríguez E., Ferrer J., Martí S., Zock J.P., Plana E., Morell F. Impact of occupational exposure on severity of COPD. Chest. 2008;134:1237–1243. doi: 10.1378/chest.08-0622. [DOI] [PubMed] [Google Scholar]
  • 82.Lam K.B., Jiang C.Q., Jordan R.E., Miller M.R., Zhang W.S., Cheng K.K. Smoking and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest. 2010;137:593–600. doi: 10.1378/chest.09-1435. [DOI] [PubMed] [Google Scholar]
  • 83.Menezes A.M.B., Hallal P.C., Perez-Padilla R., Jardim J.R.B., Muiño A., Lopez M.V. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2006;30:1180–1185. doi: 10.1183/09031936.00083507. [DOI] [PubMed] [Google Scholar]
  • 84.Chronic obstructive pulmonary disease: risk factors and risk reduction [acceso julio 2009]. Disponible en: http://www.uptodate.com/online/.
  • 85.Kohnlein T., Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med. 2008;121:3–9. doi: 10.1016/j.amjmed.2007.07.025. [DOI] [PubMed] [Google Scholar]
  • 86.Miravitlles M., Herr C., Ferrarotti I., Jardi R., Rodriguez-Frias F., Luisetti M. Laboratory testing of individuals with severe AAT deficiency in three European centres. Eur Respir J. 2010;35:960–968. doi: 10.1183/09031936.00069709. [DOI] [PubMed] [Google Scholar]
  • 87.Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–773. doi: 10.1016/S0140-6736(07)61380-4. [DOI] [PubMed] [Google Scholar]
  • 88.Roche N., Marthan R., Berger P., Chambellan A., Chanez P., Aguilaniu B. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev. 2011;20:175–182. doi: 10.1183/09059180.00004211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Yang I.A., Relan V., Wright C.M., Davidson M.R., Sriram K.B., Savarimuthu Francis S.M. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets. 2011;15:439–456. doi: 10.1517/14728222.2011.555400. [DOI] [PubMed] [Google Scholar]
  • 90.Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555. doi: 10.1513/pats.200709-148ET. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Barnes P., Celli B.R. Systemic manifestations and comorbidities in COPD. Eur Respir J. 2009;33:1165–1185. doi: 10.1183/09031936.00128008. [DOI] [PubMed] [Google Scholar]
  • 92.Soriano J.B., Sauleda J. Chapter 12. How the COPD patient should be assessed for co-morbidities. In: Rennard I., editor. Clinical management of chronic obstructive lung disease. 2nd. Informa Healthcare; Boston: 2007. [Google Scholar]
  • 93.Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi: 10.1056/NEJMoa063070. [DOI] [PubMed] [Google Scholar]
  • 94.Soriano J.B., Visick G.T., Muellerova H., Payvandi N., Hansell A.L. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107. doi: 10.1378/chest.128.4.2099. [DOI] [PubMed] [Google Scholar]
  • 95.Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008;32:962–969. doi: 10.1183/09031936.00012408. [DOI] [PubMed] [Google Scholar]
  • 96.Almagro P., López García F., Cabrera F.J., Montero L., Morchón D., Díez J. Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study. Rev Clin Esp. 2010;210:101–108. doi: 10.1016/j.rce.2009.12.002. [DOI] [PubMed] [Google Scholar]
  • 97.Finkelstein J., Cha E., Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–349. doi: 10.2147/copd.s6400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Feary J.R., Rodrigues L.C., Smith C.J., Hubbard R.B., Gibson J.E. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956–962. doi: 10.1136/thx.2009.128082. [DOI] [PubMed] [Google Scholar]
  • 99.Donaldson G.C., Hurst J.R., Smith C.J., Hubbard R.B., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091–1097. doi: 10.1378/chest.09-2029. [DOI] [PubMed] [Google Scholar]
  • 100.Rutten F.H., Cramer M.J., Grobbee D.E., Sachs A.P., Kirkels J.H., Lammers J.W. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–1894. doi: 10.1093/eurheartj/ehi291. [DOI] [PubMed] [Google Scholar]
  • 101.Render M.L., Weinstein A.S., Blaustein A.S. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest. 1995;107:162–168. doi: 10.1378/chest.107.1.162. [DOI] [PubMed] [Google Scholar]
  • 102.Almagro P., Calbo E., Ochoa de Echagüen A., Barreiro B., Quintana S., Heredia J.L. Mortality after hospitalization for COPD. Chest. 2002;121:1441–1448. doi: 10.1378/chest.121.5.1441. [DOI] [PubMed] [Google Scholar]
  • 103.Barr R.G., Bluemke D.A., Ahmed F.S., Carr J.J., Enright P.L., Hoffman E.A. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217–227. doi: 10.1056/NEJMoa0808836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34:380–386. doi: 10.1183/09031936.00144208. [DOI] [PubMed] [Google Scholar]
  • 105.Brenner D.R., McLaughlin J.R., Hung R.J. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE. 2011;6:e17479. doi: 10.1371/journal.pone.0017479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Yohannes A.M., Willgoss T.G., Baldwin R.C., Connolly M.J. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25:1209–1221. doi: 10.1002/gps.2463. [DOI] [PubMed] [Google Scholar]
  • 107.Ng T.P., Niti M., Tan W.C., Cao Z., Ong K.C., Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60–67. doi: 10.1001/archinte.167.1.60. [DOI] [PubMed] [Google Scholar]
  • 108.Mortensen E.M., Copeland L.A., Pugh M.J., Restrepo M.I., De Molina R.M., Nakashima B. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45. doi: 10.1186/1465-9921-10-45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Salpeter S., Ormiston T., Salpeter E. Betabloqueantes cardioselectivos para la enfermedad pulmonar obstructiva crónica (Revisión Cochrane traducida) La Biblioteca Cochrane Plus. 2008 Número 4. [Google Scholar]
  • 110.Short P.M., Lipworth S.I., Elder D.H., Schembri S., Lipworth B.J. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Br Med J. 2011;10:d2549. doi: 10.1136/bmj.d2549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Decramer M., Celli B., Kesten S., Lystig T., Mehra S., Tashkin D.P., UPLIFT investigators Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–1178. doi: 10.1016/S0140-6736(09)61298-8. [DOI] [PubMed] [Google Scholar]
  • 112.Jenkins C.R., Jones P.W., Calverley P.M. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59. doi: 10.1186/1465-9921-10-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Donaldson G.C., Seemugal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852. doi: 10.1136/thorax.57.10.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Vestbo J., Edwards E.D., Scanlon P.D., Yates J.C., Agustí A., Bakke P. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–1192. doi: 10.1056/NEJMoa1105482. [DOI] [PubMed] [Google Scholar]
  • 115.Rennard S.I., Stolel J.K., Wilson K.C. Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging. 2011 Uptodate v16.1 [accedido Abr Disponible en: http://www.uptodate.com/online/ [Google Scholar]
  • 116.Sanchís Aldás J., Casan Clarà P., Castillo Gómez J., Honzález Mangado N., Palenciano Ballesteros L., Roca Torrent J. Normativa para la práctica de la espirometría forzada. Arch Bronconeumol. 1989;25:132–142. [Google Scholar]
  • 117.Monteagudo M., Rodriguez-Blanco T., Parcet J., Peñalver N., Rubio C., Ferrer M. Variabilidad en la realización de la espirometría y sus consecuencias en el tratamiento de la EPOC en Atención Primaria. Arch Bronconeumol. 2011;47:226–233. doi: 10.1016/j.arbres.2010.10.009. [DOI] [PubMed] [Google Scholar]
  • 118.Naberan K., De la Roza C., Lamban M., Gobartt E., Martín A., Miravitlles M. Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in Primary Care. Arch Bronconeumol. 2006;42:638–644. doi: 10.1016/s1579-2129(07)60006-8. [DOI] [PubMed] [Google Scholar]
  • 119.Hardie J.A., Buist A.S., Vollmer W.M., Ellingsen I., Bakke P.S., Morkve O. Risk of overdiagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20:1117–1122. doi: 10.1183/09031936.02.00023202. [DOI] [PubMed] [Google Scholar]
  • 120.Celli B.R., Halbert R.J., Isonaka S., Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22:268–273. doi: 10.1183/09031936.03.00075102. [DOI] [PubMed] [Google Scholar]
  • 121.Matthay R.A., Niederman M.S., Wiedemann H.P. Cardiovascular-pulmonary interaction in chronic obstructive pulmonary disease with special reference to the pathogenesis and management of cor pulmonale. Med Clin North Am. 1990;74:571. doi: 10.1016/s0025-7125(16)30541-7. [DOI] [PubMed] [Google Scholar]
  • 122.Badgett R.G., Tanaka D.J., Hunt D.K. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med. 1993;94:188. doi: 10.1016/0002-9343(93)90182-o. [DOI] [PubMed] [Google Scholar]
  • 123.Miniati M., Monti S., Stolk J., Mirarchi G., Falaschi F., Rabinovich R. Value of chest radiography in phenotyping chronic obstructive pulmonary disease. Eur Respir J. 2008;31:509–514. doi: 10.1183/09031936.00095607. [DOI] [PubMed] [Google Scholar]
  • 124.Grydeland T.B., Dirksen A., Coxson H.O., Eagan T.M.L., Thorsen E., PIllai S.G. Quantitative computed tomography measures of emphysema and airway Wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181:353–359. doi: 10.1164/rccm.200907-1008OC. [DOI] [PubMed] [Google Scholar]
  • 125.Mair G., Maclay J., Miller J.J., MacAllister D., Connell M., Murchison J.T. Airway dimensions in COPD: relationship with clinical variables. Respir Med. 2010;104:1683–1690. doi: 10.1016/j.rmed.2010.04.021. [DOI] [PubMed] [Google Scholar]
  • 126.Yuan R., Hogg J.C., Sin D.D. Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomography. Thorax. 2009;64:944–949. doi: 10.1136/thx.2008.112433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Haruna A., Muro S., Nakano Y., Ohara T., Hoshino Y., Ogawa E. CT scan findings of emphysema predict mortality in COPD. Chest. 2010;138:635–640. doi: 10.1378/chest.09-2836. [DOI] [PubMed] [Google Scholar]
  • 128.Vendrell M., De Gracia J., Olveira C., Martínez M.A., Girón R., Máiz L. Diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol. 2008;44:629–640. doi: 10.1157/13128330. [DOI] [PubMed] [Google Scholar]
  • 129.John M., Hoernig S., Doehner W., Okonko D.D., Witt C., Anker S.D. Anemia and inflammation in COPD. Chest. 2005;127:825–829. doi: 10.1378/chest.127.3.825. [DOI] [PubMed] [Google Scholar]
  • 130.Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting Bull World Health Organ. 1997;75:397–415. [PMC free article] [PubMed] [Google Scholar]
  • 131.Vilaró J. Prueba de la marcha de los 6 minutos. En: Burgos Rincón F, Casan Clará P, coordinadores. Manual de procedimientos SEPAR n.° 4: Procedimientos de evaluación de la función pulmonar-II. Madrid: SEPAR; 2004. p. 100-13.
  • 132.Boushey H., Enright P., Samet J. spirometry for chronic obstructive pulmonary disease case finding in primary care? Am J Respir Crit Care Med. 2005;172:1481–1486. doi: 10.1164/rccm.2509009. [DOI] [PubMed] [Google Scholar]
  • 133.Wilt T.J., Niewoehner D., Kim C. Agency for Healthcare Research and Quality; Rockville, MD: 2005. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Summary, Evidence Report/Technology Assessment: Number 121. AHRQ Publication Number 05-E017-1. August, Disponible en: http://www.ahrq.gov/clinic/epcsums/spirosum.htm. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Miravitlles M., Llor C., Calvo E., Díaz S., Díaz-Cuervo H., González-Rojas N. Validación de la versión traducida del chronic obstructive pulmonary disease-population screener (COPD-PS). Su utilidad y la del FEV1/FEV6 para el diagnóstico de EPOC. Med Clin (Barc) 2012 doi: 10.1016/j.medcli.2011.06.022. (en prensa) [DOI] [PubMed] [Google Scholar]
  • 135.Martinez F.J., Raczek A.E., Seifer F.D., Conoscenti C.S., Curtice T.G., D’Eletto T. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS) COPD. 2008;5:85–95. doi: 10.1080/15412550801940721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Van Schayck C.P., Loozen J.M.C., Wagena E., Akkermans R.P., Wesseling G.J. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. Br Med J. 2002;324:1370. doi: 10.1136/bmj.324.7350.1370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Rodríguez Nieto M.J., Galán Gallego J., Martín García M., Batanero A., García E., Peces-Barba G. Fiabilidad y facilidad de uso de un nuevo espirómetro portátil en el diagnóstico de la EPOC. Rev Patol Respir. 2011;14:53–89. [Google Scholar]
  • 138.Jing J.Y., Huang T.C., Cui W., Xu F., Shen H.H. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A meta-analysis. Chest. 2009;135:991–998. doi: 10.1378/chest.08-0723. [DOI] [PubMed] [Google Scholar]
  • 139.Represas Represas C., Botana Rial M., Leiro Fernández V., González Silva A.I., Del Campo Pérez V., Fernandez-Villar A. Validación del dispositivo portátil COPD-6 para la detección de patologías obstructivas de la vía aérea. Arch Bronconeumol. 2010;46:426–432. doi: 10.1016/j.arbres.2010.04.008. [DOI] [PubMed] [Google Scholar]
  • 140.Soler-Cataluña J.J., Cosío B., Izquierdo J.L., López-Campos J.L., Marín J.M., Agüero R. Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. Arch Bronconeumol. 2012 (en prensa) [Google Scholar]
  • 141.Miravitlles M., Marin A., Monsó E., Vilà S., De la Roza C., Hervás R. Colour of sputum is a marker of bacterial colonization in COPD. Respir Res. 2010;11:58. doi: 10.1186/1465-9921-11-58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142.Burrows B., Earle R.H. Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis. 1969;99:865–871. doi: 10.1164/arrd.1969.99.6.865. [DOI] [PubMed] [Google Scholar]
  • 143.Nishimura K., Izumi T., Tsukino M., Oga T. en representación del Kansai COPD registry and research group in Japan. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440. doi: 10.1378/chest.121.5.1434. [DOI] [PubMed] [Google Scholar]
  • 144.Pinto-Plata V.M., Cote C., Cabral H., Taylor J., Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28–33. doi: 10.1183/09031936.03.00034603. [DOI] [PubMed] [Google Scholar]
  • 145.Celli B.R., Cote C.G., Marín J.M., Casanova C., Montes de Oca M., Mendez R.A. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012. doi: 10.1056/NEJMoa021322. [DOI] [PubMed] [Google Scholar]
  • 146.Ong K.C., Earnest A., Lu S.J. A Multidimensional grading system (BODE Index) as predictor of hospitalization for COPD. Chest. 2005;128:3810–3816. doi: 10.1378/chest.128.6.3810. [DOI] [PubMed] [Google Scholar]
  • 147.An L., Lin Y.X., Yang T., Zhang H., Jiao X., Zhang S. Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease. Chin Med J. 2010;123:1845–1851. [PubMed] [Google Scholar]
  • 148.Cote C.G., Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J. 2005;26:630–636. doi: 10.1183/09031936.05.00045505. [DOI] [PubMed] [Google Scholar]
  • 149.Imfeld S., Bloch K.E., Weder W., Russi E.W. The BODE index after lung volume reduction correlates with survival in COPD. Chest. 2006;129:835–836. doi: 10.1378/chest.129.4.873. [DOI] [PubMed] [Google Scholar]
  • 150.Soler-Cataluña J.J., Martínez-García M.A., Sánchez L., Perpiña M., Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103:692–699. doi: 10.1016/j.rmed.2008.12.005. [DOI] [PubMed] [Google Scholar]
  • 151.Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586. doi: 10.1136/thx.54.7.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Esteban C., Quintana J.M., Aburto M., Moraza J., Egurrola M., Pérez-Izquierdo J. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J. 2010;36:292–300. doi: 10.1183/09031936.00021409. [DOI] [PubMed] [Google Scholar]
  • 153.García-Aymerich J., Lange P., Benet M., Schnohr P., Antó J.M. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:458–463. doi: 10.1164/rccm.200607-896OC. [DOI] [PubMed] [Google Scholar]
  • 154.Waschki B., Kirsten A., Holz O., Müller K.C., Meyer T., Watz H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD. Chest. 2011;140:331–342. doi: 10.1378/chest.10-2521. [DOI] [PubMed] [Google Scholar]
  • 155.Pitta F., Troosters T., Probst V.S., Spruit M.A., Decramer M., Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006;27:1040–1055. doi: 10.1183/09031936.06.00064105. [DOI] [PubMed] [Google Scholar]
  • 156.Watz H., Waschki B., Meyer T., Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262–272. doi: 10.1183/09031936.00024608. [DOI] [PubMed] [Google Scholar]
  • 157.García-Aymerich J., Serra Pons I., Mannino D.M., Maas A.K., Miller D.P., Davis K.J. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011;66:585–590. doi: 10.1136/thx.2010.152876. [DOI] [PubMed] [Google Scholar]
  • 158.Jones P.W., Harding G., Berry P., Wiklund I., Chen W.-H., Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–654. doi: 10.1183/09031936.00102509. [DOI] [PubMed] [Google Scholar]
  • 159.Jones P., Harding G., Wiklund I., Berry P., Leidy N. Improving the process and outcome of care in COPD: development of a standardised assessment tool. Prim Care Respir J. 2009;18:208–215. doi: 10.4104/pcrj.2009.00053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Jones P., Tabberer M., Chen W.G. Creating scenarios of the impact of COPD and their relationship to COPD asessment test (CATTM) socres. BMC Pulm Med. 2011;11:42. doi: 10.1186/1471-2466-11-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161.Jones P.W., Brusselle G., Dal Negro R.W., Ferrer M., Kardos P., Levy M.L. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:29–35. doi: 10.1183/09031936.00177210. [DOI] [PubMed] [Google Scholar]
  • 162.Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E. The effects of a smoking cessation intervention on 14,5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–239. doi: 10.7326/0003-4819-142-4-200502150-00005. [DOI] [PubMed] [Google Scholar]
  • 163.Godtfredsen N.S., Lam T.H., Hansel T.T., Leon M.E., Gray N., Dresler C. COPD related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32:844–853. doi: 10.1183/09031936.00160007. [DOI] [PubMed] [Google Scholar]
  • 164.Hylkema M.N., Sterk P.J., De Boer W.I., Postma D.S. Tobacco use in relation to COPD and asthma. Eur Respir J. 2007;29:438–445. doi: 10.1183/09031936.00124506. [DOI] [PubMed] [Google Scholar]
  • 165.Wagena E.J., Zeegers M.P.A., Van Schayck C.P., Wouters E.F.M. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf. 2003;26:381–403. doi: 10.2165/00002018-200326060-00002. [DOI] [PubMed] [Google Scholar]
  • 166.Jiménez Ruiz C.A., De Granda Orive J.I., Riesco Miranda J.A. Abordaje diagnóstico y terapéutico del tabaquismo en EPOC. In: Güell R., De Lucas P., editors. Tratado de rehabilitación respiratoria. Ars Medica; Madrid: 2005. [Google Scholar]
  • 167.Jiménez C.A., Masa F., Miravitlles M., Gabriel R., Viejo J.L., Villasante C. Smoking characteristics: attitudes and dependence. Differences between healthy smokers and smokers with COPD. Chest. 2001;119:1365–1373. doi: 10.1378/chest.119.5.1365. [DOI] [PubMed] [Google Scholar]
  • 168.Fiore M.C., Jaén C.R., Baker T.G., Bailey W.C., Benowitz N.L., Curry S.J. US Department of Health and Human Services, Public Health Service; Rockville, MD: 2008. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. [Google Scholar]
  • 169.Tashkin D.P., Rennard S., Taylor J., Wendy Ma, Lawrence D., Lee T.C. Effects of varenicline on smoking cessation in patients with mild to moderate COPD. A randomized controlled trial. Chest. 2011;139:591–599. doi: 10.1378/chest.10-0865. [DOI] [PubMed] [Google Scholar]
  • 170.Postma D., Anzueto A., Calverley P., Jenkins C., Make B.J., Sciurba F.C. A new perspective on optimal care for patients with COPD. Prim Care Respir J. 2011;20:205–209. doi: 10.4104/pcrj.2011.00041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1) doi: 10.1002/14651858.CD002733.pub2. CD002733. [DOI] [PubMed] [Google Scholar]
  • 172.Michiels B., Govaerts F., Remmen R., Vermeire E., Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29:9159–9170. doi: 10.1016/j.vaccine.2011.08.008. [DOI] [PubMed] [Google Scholar]
  • 173.Walters J.A., Smith S., Poole P., Granger R.H., Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(11) doi: 10.1002/14651858.CD001390.pub3. CD001390. [DOI] [PubMed] [Google Scholar]
  • 174.Alfageme I., Vazquez R., Reyes N., Muñoz J., Fernández A., Hernandez M. Clinical efficacy of anti-pneumococcal vaccination inpatients with COPD. Thorax. 2006;61:189–195. doi: 10.1136/thx.2005.043323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Lopez-Campos J.L. Estrategias de tratamiento en la enfermedad pulmonar obstructiva crónica: una propuesta de sistematización. Arch Bronconeumol. 2010;46:617–620. doi: 10.1016/j.arbres.2010.06.003. [DOI] [PubMed] [Google Scholar]
  • 176.Sestini P., Renzoni E., Robinson S., Poole P., Ram F.S. Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4) doi: 10.1002/14651858.CD001495. CD001495. [DOI] [PubMed] [Google Scholar]
  • 177.Boyd G., Morice A.H., Pounsford J.C., Siebert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of the chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997;10:815–821. [PubMed] [Google Scholar]
  • 178.Aalbers R., Ayres J., Backer V., Decramer M., Lier P.A., Magyar P. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936–943. doi: 10.1183/09031936.02.00240902. [DOI] [PubMed] [Google Scholar]
  • 179.Stockley R.A., Whitehead P.J., Williams M.K. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res. 2006;7:147. doi: 10.1186/1465-9921-7-147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180.Tashkin D.P., Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249–259. doi: 10.1378/chest.125.1.249. [DOI] [PubMed] [Google Scholar]
  • 181.Beier J., Beeh K.M. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis. 2011;6:237–243. doi: 10.2147/COPD.S7371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., Kesten S. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404. doi: 10.1136/thorax.58.5.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 183.O’Donnell J., Flüge T., Gerken F., Hamilton A., Webb K., Aguilaniu B. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840. doi: 10.1183/09031936.04.00116004. [DOI] [PubMed] [Google Scholar]
  • 184.Man W.D.C., Mustfa N., Nikoletou D., Kaul S., Hart N., Rafferty G.F. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59:471–476. doi: 10.1136/thx.2003.019620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185.Celli B., Decramer M., Kesten S., Liu D., Mehra S., Tashkin D.P. Mortality in the 4-year trial of Tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948–955. doi: 10.1164/rccm.200906-0876OC. [DOI] [PubMed] [Google Scholar]
  • 186.Puhan M.A., Bachmann L.M., Kleijnen J., Ter Riet G., Kessels A.G. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009;7:2. doi: 10.1186/1741-7015-7-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187.Appleton S., Jones T., Poole P., Pilotto L., Adams R., Lasserson T.J. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2) doi: 10.1002/14651858.CD001387.pub2. CD001387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188.Appleton S., Poole P., Smith B., Veale A., Lasserson T.J., Chan M.M. Long-acting beta-2 agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;3 doi: 10.1002/14651858.CD001104.pub2. CD001104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.Wilt T.J., Niewoehner D., MacDonald R., Kane R.L. management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147:639–653. doi: 10.7326/0003-4819-147-9-200711060-00009. [DOI] [PubMed] [Google Scholar]
  • 190.Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi: 10.1056/NEJMoa0805800. [DOI] [PubMed] [Google Scholar]
  • 191.Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten van Molkën M.P.M.H., Beeh K.M. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–1103. doi: 10.1056/NEJMoa1008378. [DOI] [PubMed] [Google Scholar]
  • 192.Barr R.G., Bourbeau J., Camargo C.A., Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a metaanalysis. Thorax. 2006;61:854–862. doi: 10.1136/thx.2006.063271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193.Van Noord J.A., Aumann J.-L., Janssens E., Smeets J.J., Verhaert J., Disse B. Comparison of tiotropium once daily, formoterol twice daily and both combined oncedaily in patients with COPD. Eur Respir J. 2005;26:214–222. doi: 10.1183/09031936.05.00140404. [DOI] [PubMed] [Google Scholar]
  • 194.Van Noord J.A., Buhl R., LaForce C., Martin C., Jones F., Dolker M. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010;65:1086–1091. doi: 10.1136/thx.2010.139113. [DOI] [PubMed] [Google Scholar]
  • 195.Ram F.S.F., Jardim J.R., Atallah A. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005;99:135–144. doi: 10.1016/j.rmed.2004.10.009. [DOI] [PubMed] [Google Scholar]
  • 196.Zhou Y., Wang X., Zeng X., Qiu R., Xie J., Liu S. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of lowdose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006;11:603–610. doi: 10.1111/j.1440-1843.2006.00897.x. [DOI] [PubMed] [Google Scholar]
  • 197.American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900. doi: 10.1164/rccm.168.7.818. [DOI] [PubMed] [Google Scholar]
  • 198.Task Force on COPD Moving towards a new focus on COPD. The Spanish COPD guidelines (GESEPOC) Arch Bronconeumol. 2011;47:379–381. doi: 10.1016/j.arbres.2011.05.008. [DOI] [PubMed] [Google Scholar]
  • 199.Papi A., Romagnoli M., Baraldo S. Partial reversibility of airflow limitation and incresead exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1773–1777. doi: 10.1164/ajrccm.162.5.9910112. [DOI] [PubMed] [Google Scholar]
  • 200.Miravitlles M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol. 2011;47:271. doi: 10.1016/j.arbr.2011.01.003. [DOI] [PubMed] [Google Scholar]
  • 201.Siva R., Green R.H., Brightling C.E., Shelley M., Hargadon B., McKenna S. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906–913. doi: 10.1183/09031936.00146306. [DOI] [PubMed] [Google Scholar]
  • 202.GEMA 2009 Guía Española para el Manejo del Asma 2009. Arch Bronconeumol. 2009;45:2–35. doi: 10.1016/S0300-2896(15)32812-X. [DOI] [PubMed] [Google Scholar]
  • 203.Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–750. doi: 10.1164/rccm.200904-0492OC. [DOI] [PubMed] [Google Scholar]
  • 204.Peters S.P., Kunselman S.J., Nikolina Icitovic M.A., Moore W.C., Pascual R., Ameredes B.T. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–1726. doi: 10.1056/NEJMoa1008770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205.American Thoracic Society Standards for diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:77–121. [PubMed] [Google Scholar]
  • 206.Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555. doi: 10.1164/rccm.200703-456SO. [DOI] [PubMed] [Google Scholar]
  • 207.Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144–149. doi: 10.1164/rccm.200602-244OC. [DOI] [PubMed] [Google Scholar]
  • 208.Szafransky W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S. Efficacy and safety of budesonide/formoterol and formoterol in chronic obstructive pulmonary diseases. Eur Respir J. 2003;21:74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  • 209.Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and longacting beta-agonistin one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(2) doi: 10.1002/14651858.CD006829. CD006829. [DOI] [PubMed] [Google Scholar]
  • 210.Sobieraj D.M., White C.M., Coleman C.I. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a metaanalysis. Clin Ther. 2008;30:1416–1425. doi: 10.1016/j.clinthera.2008.08.004. [DOI] [PubMed] [Google Scholar]
  • 211.Nieto A., Mazon A., Pamies R. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med. 2007;167:2047–2053. doi: 10.1001/archinte.167.19.2047. [DOI] [PubMed] [Google Scholar]
  • 212.Scanlon P.D., Connett J.E., Wise R.A. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med. 2004;170:1302–1309. doi: 10.1164/rccm.200310-1349OC. [DOI] [PubMed] [Google Scholar]
  • 213.Calverley P.M.A., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructivepulmonary disease. Am J Respir Crit Care Med. 2007;176:154–161. doi: 10.1164/rccm.200610-1563OC. [DOI] [PubMed] [Google Scholar]
  • 214.Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555. doi: 10.7326/0003-4819-146-8-200704170-00152. [DOI] [PubMed] [Google Scholar]
  • 215.Karner C., Cates C.J. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2011;(Issue 9) doi: 10.1002/14651858.CD009039.pub2. Art. No.: CD009039. DOI:10.1002/14651858.CD009039.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216.Barnes P.J. Theophylline for COPD. Thorax. 2006;61:742–744. doi: 10.1136/thx.2006.061002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217.Cosio B.G., Tsaprouni L., Ito K., Jazrawi E., Adcock I.M., Barnes P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200:689–695. doi: 10.1084/jem.20040416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Fabbri L.M., Calverley P.M.A., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi: 10.1016/S0140-6736(09)61252-6. [DOI] [PubMed] [Google Scholar]
  • 219.Bateman E.D., Rabe K.F., Calverley P.M.A., Goehring U.M., Brose M., Bredenbroker D. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38:553–560. doi: 10.1183/09031936.00178710. [DOI] [PubMed] [Google Scholar]
  • 220.Rennard S.I., Calverley P.M.A., Goehring U.M. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi: 10.1186/1465-9921-12-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Grandjean E.M., Berthet P., Ruffmann R., Leuenberger M. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a metaanalysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209–221. doi: 10.1016/S0149-2918(00)88479-9. [DOI] [PubMed] [Google Scholar]
  • 222.Sutherland E.R., Crapo J.D., Bowler R.P. N-Acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3:195–202. doi: 10.1080/15412550600977361. [DOI] [PubMed] [Google Scholar]
  • 223.Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(3) doi: 10.1002/14651858.CD001287.pub2. CD001287. [DOI] [PubMed] [Google Scholar]
  • 224.Zheng J.P., Kang J., Huang S.G. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebocontrolled study. Lancet. 2008;371:2013–2018. doi: 10.1016/S0140-6736(08)60869-7. [DOI] [PubMed] [Google Scholar]
  • 225.Decramer M., Rutten-van M.M., Dekhuijzen P.N., Troosters T., Van Herwaarden C., Pellegrion R. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study. BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552–1560. doi: 10.1016/S0140-6736(05)66456-2. [DOI] [PubMed] [Google Scholar]
  • 226.Staykova T., Black P.N., Chacko E.E., Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Review. 2009 doi: 10.1002/14651858.CD004105. Published online: 21 Jan, DOI:10.1002/14651858. CD004105. [DOI] [PubMed] [Google Scholar]
  • 227.Sevilla-Sánchez D., Soy-Muner D., Soler-Porcar N. Utilidad de los macrólidos como antiinflamatorios en las enfermedades respiratorias. Arch Bronconeumol. 2010;46:244–254. doi: 10.1016/j.arbres.2009.10.008. [DOI] [PubMed] [Google Scholar]
  • 228.Seemungal T.A.R., Wilkinson T.M.A., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–1147. doi: 10.1164/rccm.200801-145OC. [DOI] [PubMed] [Google Scholar]
  • 229.Pomares X., Montón C., Espasa M., Casabon J., Monsó E., Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obst Respir Dis. 2011;6:449–456. doi: 10.2147/COPD.S23655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230.Albert R.K., Connett J., Biley W.C., Casaburi R., Cooper J.A.D., Criner G.J. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698. doi: 10.1056/NEJMoa1104623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231.Miravitlles M., Marín A., Monsó E., Vilà S., De la Roza C., Hervás R. Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD. Eur Respir J. 2009;34:1066–1071. doi: 10.1183/09031936.00195608. [DOI] [PubMed] [Google Scholar]
  • 232.Sethi S., Jones P.W., Theron M.S., Miravitlles M., Rubinstein E., Wedzicha J.A. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10. doi: 10.1186/1465-9921-11-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 233.Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–2365. doi: 10.1056/NEJMra0800353. [DOI] [PubMed] [Google Scholar]
  • 234.Adams S.G., Anzueto A., Briggs D.D., Jr., Leimer I., Kesten S. Evaluation of withdrawal of maintenance tiotropium in COPD. Respir Med. 2009;103:1415–1420. doi: 10.1016/j.rmed.2009.05.018. [DOI] [PubMed] [Google Scholar]
  • 235.Van der Valk P., Monninkhof E., Van del Palen J., Zielhuis G., Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med. 2002;166:1358–1363. doi: 10.1164/rccm.200206-512OC. [DOI] [PubMed] [Google Scholar]
  • 236.Nighat J., Nadeem N.J., Taylor S., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD: a systematic review and comment on trial methodology. Respir Res. 2011;12:107. doi: 10.1186/1465-9921-12-107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237.Schermer T.R.J., Hendriks A.J.C., Chavannes N.H., Dekhuijzen P.N.R., Wouters E.F.M., Van der Hoogen H. probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J. 2004;13:48–55. doi: 10.1016/j.pcrj.2003.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 238.Liesker J.J.W., Bathoorn E., Postma D.S., Vonk J.M., Timens W., Kerstjens H.A.M. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011;105:1853–1860. doi: 10.1016/j.rmed.2011.07.002. [DOI] [PubMed] [Google Scholar]
  • 239.Cranston J.M., Crockett A.J., Moss J.R., Alpers J.H. Domiciliary oxygen for COPD. Cochrane Database Syst Rev. 2005 doi: 10.1002/14651858.CD001744.pub2. CD001744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 240.Report of Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981:681–686. [PubMed] [Google Scholar]
  • 241.Nocturnal Oxygen Therapy Trial Group Continuous of nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. An Intern Med. 1980;93:391–398. doi: 10.7326/0003-4819-93-3-391. [DOI] [PubMed] [Google Scholar]
  • 242.Kim V., Benditt J.O., Wise R.A., Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:513–518. doi: 10.1513/pats.200708-124ET. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 243.Chailleux E., Fauroux B., Bidet F., Dautzenberg B., Polu J.M. Predictors of survival in patients receiving domiciliary oxigen therapy or mechanical ventilation. A 10- year analysis of ANTADIR Observatory. Chest. 1996;109:741–749. doi: 10.1378/chest.109.3.741. [DOI] [PubMed] [Google Scholar]
  • 244.O’Donell D.E., D’Arsigny C., Webb K.A. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:892–898. doi: 10.1164/ajrccm.163.4.2007026. [DOI] [PubMed] [Google Scholar]
  • 245.Wijkstra P.J., Guyatt G.H., Ambrosino N., Celli B.R., Güell R., Muir J.F. International approaches to the prescription of long-term oxygen therapy. Eur Respir J. 2001;18:909–913. doi: 10.1183/09031936.01.00202301. [DOI] [PubMed] [Google Scholar]
  • 246.Atención integral al paciente con EPOC Desde la Atención Primaria a la Especializada. Guía de práctica clínica. 2010 SEPAR-semFYC. [Google Scholar]
  • 247.Guía de práctica clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. SEPAR-ALAT, 2009.
  • 248.Bradley J.M., Lasserson T., Elborn S., Macmahon J., O’Neill B. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest. 2007;131:278–285. doi: 10.1378/chest.06-0180. [DOI] [PubMed] [Google Scholar]
  • 249.Bradley J.M., O’Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4) doi: 10.1002/14651858.CD004356.pub3. CD004356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 250.Kolodziej M.A., Jensen L., Rowe B., Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J. 2007;30:293–306. doi: 10.1183/09031936.00145106. [DOI] [PubMed] [Google Scholar]
  • 251.McEvoy R.D., Pierce R.J., Hillman D. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009;64:561–566. doi: 10.1136/thx.2008.108274. [DOI] [PubMed] [Google Scholar]
  • 252.Budweiser S., Jörres R.A., Pfeifer M. Treatment of respiratory failure in COPD. Int J COPD. 2008;3:605–618. doi: 10.2147/copd.s3814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 253.Goldberg A., Leger P., Hill N., Criner G. Clinical indications for non-invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease. OPD, and nocturnal hypoventilation. A consensus conference report. Chest. 1999;116:521–534. doi: 10.1378/chest.116.2.521. [DOI] [PubMed] [Google Scholar]
  • 254.Gay P.C. UptoDate. Nocturnal ventilatory support in COPD. 2011 Last review version: september. [Google Scholar]
  • 255.Nice L., Donner C.I., Wouters E. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–1413. doi: 10.1164/rccm.200508-1211ST. [DOI] [PubMed] [Google Scholar]
  • 256.ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel Pulmonary rehabilitation. Joint ACCP/AACVPR Evidence-Based Guidelines. Chest. 2007;131:4S–51S. doi: 10.1378/chest.06-2418. [DOI] [PubMed] [Google Scholar]
  • 257.Güell R., Resqueti V., Sangenis M. Impact of pulmonary rehabilitation on pshychosocial morbidity in patients with severe chronic obstructive pulmonary disease. Chest. 2006;129:899–904. doi: 10.1378/chest.129.4.899. [DOI] [PubMed] [Google Scholar]
  • 258.Lacasse Y., Goldstein R., Lasserson T.J., Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(4) doi: 10.1002/14651858.CD003793.pub2. CD003793. [DOI] [PubMed] [Google Scholar]
  • 259.Lötters F., Van Tol B., Kwakkel G. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002;20:570–576. doi: 10.1183/09031936.02.00237402. [DOI] [PubMed] [Google Scholar]
  • 260.British Thoracic Society Standards of care subcommittee on pulmonary rehabilitation. Thorax. 2001;56:827–834. doi: 10.1136/thorax.56.11.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 261.Beauchamp M.K., Janaudis-Ferreira T., Goldstein R.S., Brooks D. Optimal duration of pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic review. Chron Respir Dis. 2011;8:129–140. doi: 10.1177/1479972311404256. [DOI] [PubMed] [Google Scholar]
  • 262.Qaseem A., Wilt T.J., Weinberger S.E., Hanania N.A., Criner G., Van der Molen T. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians. American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191. doi: 10.7326/0003-4819-155-3-201108020-00008. [DOI] [PubMed] [Google Scholar]
  • 263.Marciniuk D.D., Brooks D., Butcher S., Debigare R., Dechman G., Ford G., Canadian Thoracic Society COPD Committee Expert Working Group Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010;17:159–168. doi: 10.1155/2010/425975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 264.Hopkinson N., Polkey M. Does physical inactivity cause chronic obstructive pulmonary disease? Clin Sci. 2010;118:565–572. doi: 10.1042/CS20090458. [DOI] [PubMed] [Google Scholar]
  • 265.Grandes G., Sánchez A., Sánchez-Pinilla R.O., Torcal J., Montoya I., Lizarraga K., PEPAF Group Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial. Arch Intern Med. 2009;169:694–701. doi: 10.1001/archinternmed.2009.23. [DOI] [PubMed] [Google Scholar]
  • 266.Ussher M.H., Taylor A., Faulkner G. Exercise interventions for smoking cessation. Cochrane Database Syst Rev. 2008 doi: 10.1002/14651858.CD002295.pub3. CD002295, doi:10.1002/14651858.CD002295. pub 3. [DOI] [PubMed] [Google Scholar]
  • 267.Juan Díaz M., Serrano Lázaro A., Mesejo Arizmendi A. Aspectos nutricionales de la patología pulmonar. Nutr Clin Med. 2008;2:141–154. [Google Scholar]
  • 268.Alcolea Batres S., Villamor León J., Álvarez-Sala R. EPOC y estado nutricional. Arch Bronconeumol. 2007;43:283–288. [PubMed] [Google Scholar]
  • 269.Martín Salinas C., Motilla Valeriano T., Valoración del estado nutricional . In: Nutrición y Dietética. 2.ª. Martín Salinas C., Motilla Valeriano T., Díaz Gómez J., Martínez Montero P., editors. DAE; Madrid: 2002. pp. 301–319. [Google Scholar]
  • 270.Martín Zurro A., Cano Pérez J.F. Atención primaria: conceptos, organización y práctica clínica. Elsevier; Barcelona: 2008. pp. 991–1006. [Google Scholar]
  • 271.Martinez F.J. Bullectomy for giant bullae in COPD. 2011 Last review version: september. [Google Scholar]
  • 272.Christie T.D., Edwards L.B., Aurora P., Dobbels F., Kirk R., Rahmel A.O. Registry of the Internacional Society for Heart and Lung Transplantation Report-2008. J Heart Lung Transplant. 2008;27:957–969. doi: 10.1016/j.healun.2008.07.018. [DOI] [PubMed] [Google Scholar]
  • 273.Lahzami S., Aubert J.D. Lung transplantation for COPD- evidence-based? Swiss Med WKI. 2009;139:4–8. doi: 10.4414/smw.2009.12377. [DOI] [PubMed] [Google Scholar]
  • 274.Normativa para la selección de pacientes candidatos a trasplante pulmonar Arch Bronconeumol. 2011;47:303–309. [Google Scholar]
  • 275.Martinez F.J. Lung volume reduction surgery in COPD. Uptodate. 2011 Last review version: september. [Google Scholar]
  • 276.Reilly J., Waskho G., Pinto-Plata V., Velez E., Kenney L., Berger R. Biological lung volume reduction:a new bronchoscopic therapy for advance emphysema. Chest. 2007;131:1108–1113. doi: 10.1378/chest.06-1754. [DOI] [PubMed] [Google Scholar]
  • 277.Berger R.L., Decamp M.M., Criner G.J., Celli B.R. Lung volume reduction therapies for advanced emphysema: an update. Chest. 2010;138:407–417. doi: 10.1378/chest.09-1822. [DOI] [PubMed] [Google Scholar]
  • 278.National Emphysema Treatment Trial Research Group Rationale and desing of the National Emphysema Treatment trial (NETT): a prospective randomized trial of lung volumen reduction surgery. J Thorac Cardiovasc Surg. 1999;118:518–528. doi: 10.1016/s0022-5223(99)70191-1. [DOI] [PubMed] [Google Scholar]
  • 279.National Emphysema Treatment Trial Research A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–2073. doi: 10.1056/NEJMoa030287. [DOI] [PubMed] [Google Scholar]
  • 280.Güell M.R., Cejudo M.P., Rodríguez-Trigo G., Gáldiz J.B., Casolive V., Reguerio M. Estándares de calidad asistencial en rehabilitación respiratoria en pacientes con enfermedad pulmonar crónica. Arch Bronconeumol. 2012 (en prensa) [Google Scholar]
  • 281.De Blasio F., Polverino M. Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease. Ther Adv Respir Dis. PMID. 2012:22563010. doi: 10.1177/1753465812444712. [DOI] [PubMed] [Google Scholar]
  • 282.Seemungal T.A.R., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  • 283.Langsetmo L., Platt R.W., Ernst P., Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396–401. doi: 10.1164/rccm.200708-1290OC. [DOI] [PubMed] [Google Scholar]
  • 284.Miravitlles M., Ferrer M., Pont A., Zalacaín R., Álvarez-Sala J.L., Masa J.F., for the IMPAC study group Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387–395. doi: 10.1136/thx.2003.008730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 285.Hurst J.R., Donaldson G.C., Perera W.R., Wilkinson T.M., Bilello J.A., Hagan G.W. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867–874. doi: 10.1164/rccm.200604-506OC. [DOI] [PubMed] [Google Scholar]
  • 286.Parker C.M., Voduc N., Aaron S.D., Webb K.A., O’Donnell D.E. Physiologic changes during symptom recovery from moderate exacerbation of COPD. Eur Respir J. 2005;26:420–428. doi: 10.1183/09031936.05.00136304. [DOI] [PubMed] [Google Scholar]
  • 287.Perera W.R., Hurst J.R., Wilkinson T.M.A., Sapsford R.J., Müllerova H., Donaldson G.C. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29:527–534. doi: 10.1183/09031936.00092506. [DOI] [PubMed] [Google Scholar]
  • 288.Soler-Cataluña J.J., Martínez-García M.A., Román-Sanchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi: 10.1136/thx.2005.040527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 289.Abroug F., Quanes-Besbes L., Nciri N., Sellami N., Addad F., Ben Hamda K. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disaase. Diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med. 2006;174:990–996. doi: 10.1164/rccm.200603-380OC. [DOI] [PubMed] [Google Scholar]
  • 290.Chang C.L., Robinson S.C., Mills G.D., Sullivan G.D., Karalus N.C., McLachlan J.D. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66:764–768. doi: 10.1136/thx.2010.155333. [DOI] [PubMed] [Google Scholar]
  • 291.Sapey E., Stockley A. COPD exacerbations: aetiology. Thorax. 2006;61:250–258. doi: 10.1136/thx.2005.041822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 292.Papi A., Bellettato C.M., Braccioni F., Romagnoli M., Casolari P., Caramori G. Infections of airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121. doi: 10.1164/rccm.200506-859OC. [DOI] [PubMed] [Google Scholar]
  • 293.Miravitlles M., Espinosa C., Fernández-Laso E., Martos J.A., Maldonado J.A., Gallego M., and Study Group of Bacterial Infection in COPD Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46. doi: 10.1378/chest.116.1.40. [DOI] [PubMed] [Google Scholar]
  • 294.Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  • 295.Stockley R.A., O’Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638–1645. doi: 10.1378/chest.117.6.1638. [DOI] [PubMed] [Google Scholar]
  • 296.Soler N., Agustí C., Angrill J., Puig de la Bellacasa J., Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29–35. doi: 10.1136/thx.2005.056374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 297.Tokmas S., Schuetz P., Bent S. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect Ther. 2011;9:727–735. doi: 10.1586/eri.11.45. [DOI] [PubMed] [Google Scholar]
  • 298.Daniels J.M., Schoorl M., Snijders D. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138:1108–1115. doi: 10.1378/chest.09-2927. [DOI] [PubMed] [Google Scholar]
  • 299.Rizkallah J., Man S.F., Sin D.D. Prevalence of pulmonary embolism in acute exacerbation of COPD: a systematic review and metaanalysis. Chest. 2009;135:786–793. doi: 10.1378/chest.08-1516. [DOI] [PubMed] [Google Scholar]
  • 300.Uresandi F., Blanquer J., Conget F., De Gregorio M.A., Lobo J.L., Otero R. Guía para el diagnóstico, tratamiento y seguimiento de la tromboembolia pulmonar. Arch Bronconeumol. 2004:580–594. doi: 10.1016/s1579-2129(06)60379-0. [DOI] [PubMed] [Google Scholar]
  • 301.McCrory D.C., Brown C., Gelfand S.E., Bach P.B. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119:1190–1209. doi: 10.1378/chest.119.4.1190. [DOI] [PubMed] [Google Scholar]
  • 302.Turner M.O., Patel A., Ginsburg S., FitzGerald J.M. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med. 1997;157:1736–1744. [PubMed] [Google Scholar]
  • 303.Boe J., Dennis J.H., O’Driscoll B.R. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18:228–242. doi: 10.1183/09031936.01.00220001. [DOI] [PubMed] [Google Scholar]
  • 304.Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbations of chronic obstructive pulmonary disease: a pilot study. Respir Med. 2006;100:1925–1932. doi: 10.1016/j.rmed.2006.03.007. [DOI] [PubMed] [Google Scholar]
  • 305.Barr R.G., Rowe B.H., Camargo C.A. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;(2) doi: 10.1002/14651858.CD002168. CD002168. [DOI] [PubMed] [Google Scholar]
  • 306.Nouira S., Marghli S., Belghith M., Besbes L., Elatrous S., Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358:2020–2025. doi: 10.1016/S0140-6736(01)07097-0. [DOI] [PubMed] [Google Scholar]
  • 307.Miravitlles M., Monsó E., Mensa J., Aguarón Pérez J., Barberán J., Bárcena Caamaño M. Tratamiento antimicrobiano de la agudización de EPOC: Documento de Consenso 2007. Arch Bronconeumol. 2008;44:100–108. doi: 10.1016/s1579-2129(08)60013-0. [DOI] [PubMed] [Google Scholar]
  • 308.Singh J.M., Palda V.A., Stanbrook M.B., Chapman K.R. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med. 2002;162:2527–2536. doi: 10.1001/archinte.162.22.2527. [DOI] [PubMed] [Google Scholar]
  • 309.Walters J.A., Gibson P.G., Wood-Baker R., Hannay M., Walters E.H. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;(1) doi: 10.1002/14651858.CD001288.pub3. CD001288. [DOI] [PubMed] [Google Scholar]
  • 310.Albert R.K., Martin T.R., Lewis S.W. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980;92:753–758. doi: 10.7326/0003-4819-92-6-753. [DOI] [PubMed] [Google Scholar]
  • 311.Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456–460. doi: 10.1016/s0140-6736(98)11326-0. [DOI] [PubMed] [Google Scholar]
  • 312.Gunen H., Hacievliyagil S.S., Yetkin O., Gulban G., Mutly L.C.E. The role of neublized budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29:660–667. doi: 10.1183/09031936.00073506. [DOI] [PubMed] [Google Scholar]
  • 313.Maltais F., Ostinelli J., Bourbeau J., Tonnel A.B., Jacquemet N., Haddon J. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165:698–703. doi: 10.1164/ajrccm.165.5.2109093. [DOI] [PubMed] [Google Scholar]
  • 314.Otero R., Grau E., Jiménez D., Uresandi F., López J.L., Calderón E. Profilaxis de la enfermedad tromboémbólica venosa. Arch Bronconeumol. 2008;44:160–169. doi: 10.1016/s1579-2129(08)60031-2. [DOI] [PubMed] [Google Scholar]
  • 315.Puhan M.A., Gimeno-Santos E., Scharplatz M., Troosters T., Walters E.H., Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(10) doi: 10.1002/14651858.CD005305.pub3. CD005305. [DOI] [PubMed] [Google Scholar]
  • 316.Burtin C., Decramer M., Gosselink R., Janssens W., Troosters T. Rehabilitation and acute exacerbations. Eur Respir Dis. 2011;38:702–712. doi: 10.1183/09031936.00079111. [DOI] [PubMed] [Google Scholar]
  • 317.Lightowler J.V., Wedzicha J.A., Elliott M.W., Ram F.S. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Br Med J. 2003;326:185–187. doi: 10.1136/bmj.326.7382.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 318.Hernandez C., Casas A., Escarrabill J., Alonso J., Puig-Junoy J., Farrero E. Home hospitalization of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J. 2003;21:58–67. doi: 10.1183/09031936.03.00015603. [DOI] [PubMed] [Google Scholar]
  • 319.Ram F.S., Wedzicha J.A., Wright J., Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. Br Med J. 2004;329:315. doi: 10.1136/bmj.38159.650347.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 320.National Cancer Institute. Disponible en: http://www.cancer.gov/.
  • 321.Curtis J.R. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32:796–803. doi: 10.1183/09031936.00126107. [DOI] [PubMed] [Google Scholar]
  • 322.Temel J.S., Greer J.A., Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742. doi: 10.1056/NEJMoa1000678. [DOI] [PubMed] [Google Scholar]
  • 323.Gore J.M., Brophy C.J., Greenstone M.A. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)?. A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55:1000–1006. doi: 10.1136/thorax.55.12.1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 324.Steinhauser K.E., Arnold R.M., Olsen M.K., Lindquist J., Hays J., Wood L.L. Comparing three life-limiting diseases: does diagnosis matter or is sick, sick? J Pain Symptom Manage. 2011;42:331–341. doi: 10.1016/j.jpainsymman.2010.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 325.Bausewein C., Booth S., Gysels M. Understanding breathlessness: crosssectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med. 2010;13:1109–1118. doi: 10.1089/jpm.2010.0068. [DOI] [PubMed] [Google Scholar]
  • 326.Lohne V., Heer H.C., Andersen M. Qualitative study of pain of patients with chronic obstructive pulmonary disease. Heart Lung. 2010;39:226–234. doi: 10.1016/j.hrtlng.2009.08.002. [DOI] [PubMed] [Google Scholar]
  • 327.Horton R., Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr Opin Support Palliat Care. 2010;4:56–62. doi: 10.1097/SPC.0b013e328338c1c6. [DOI] [PubMed] [Google Scholar]
  • 328.Pinnock H., Kendall M., Murray S.A. Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. Br Med J. 2011:d142. doi: 10.1136/bmj.d142. doi: 10. 1136/bmj. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 329.Small N., Gardiner C., Barnes S. Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. Palliat Med. 2010;24:740. doi: 10.1177/0269216310375861. [DOI] [PubMed] [Google Scholar]
  • 330.Hardin K., Meyers F., Louie S. Integrating palliative care in severe chronic obstructive lung disease. COPD. 2008;5:207–220. doi: 10.1080/15412550802237366. [DOI] [PubMed] [Google Scholar]
  • 331.Bausewein C., Booth S., Gysels M., Higginson I. Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases. Cochrane Database Syst Rev. 2008 doi: 10.1002/14651858.CD005623.pub2. CD005623. [DOI] [PubMed] [Google Scholar]
  • 332.Jennings A.L., Davies A.N., Higgins J.P. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–944. doi: 10.1136/thorax.57.11.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 333.Abernethy A.P., Currow D.C., Frith P. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. Br Med J. 2003;327:523–528. doi: 10.1136/bmj.327.7414.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 334.Jennings A.L., Davies A.N., Higgins J.P.T., Broadley K. Update Software Ltd; Oxford: 2008. Tratamiento paliativo con opiáceos para la disnea de la enfermedad terminal (Revisión Cochrane traducida). Biblioteca Cochrane Plus. Número 4, Disponible en: http://www.update-software.com. [Google Scholar]
  • 335.Goodridge D., Lawson J., Rocker G., Marciniuk D., Rennie D. Factors associated with opioid dispensation for patients with COPD and lung cancer in the last year of life: a retrospective analysis. Int J Chron Obstruct Pulmon Dis. 2010;5:99–105. doi: 10.2147/copd.s9938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 336.Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010;16:150–154. doi: 10.1097/MCP.0b013e3283364378. [DOI] [PubMed] [Google Scholar]
  • 337.Simon S.T., Higginson I.J., Booth S. Update Software Ltd; Oxford: 2010. Benzodiazepinas para el alivio de la disnea en adultos con enfermedades malignas y benignas. Biblioteca Cochrane Plus. Número 1, Disponible en: http://www.updatesoftware.com. [Google Scholar]
  • 338.Putman-Casdorph H., McCrone S. Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. Heart Lung. 2009;38:34–47. doi: 10.1016/j.hrtlng.2008.02.005. [DOI] [PubMed] [Google Scholar]
  • 339.Sociedad Española de Cuidados Paliativos. Cuidados paliativos: la familia de la persona enferma. Disponible en: http://www.secpal.com/guiasm/index. php?acc=see_guia&id_guia=4.
  • 340.Normativas SEPAR: Recomendaciones sobre la atención al final de la vida en pacientes con EPOC. Disponible en: http://www.separ.es/publicaciones/normativa/normativa_052.html. [DOI] [PubMed]
  • 341.Escarrabill J., Soler Cataluña J.J., Hernández C. Recommendations for End-of- Life Care in Patients With Chronic Obstructive Pulmonary Disease. Arch Bronconeumol. 2009;45:297–303. doi: 10.1016/j.arbres.2008.11.005. [DOI] [PubMed] [Google Scholar]
  • 342.Romero Roy M.E., Jimeno Salgado J.F. Yoga y EPOC. Abordaje desde las técnicas respiratorias. Medicina Naturista. 2007;(I):30–35. [Google Scholar]
  • 343.Hutton W. Putting the public at the heart of the NHS. Br Med J. 2007;334:69–70. doi: 10.1136/bmj.39080.574699.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 344.Health literacy: report of the Council on Scientific Affairs Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association. JAMA. 1999;281:552–557. [PubMed] [Google Scholar]
  • 345.Dewalt D.A., Berkman N.D., Sheridan S., Lohr K.N., Pignone M.P. Literacy and health outcomes: a systematic review of the literature. J Gen Intern Med. 2004;19:1228–1239. doi: 10.1111/j.1525-1497.2004.40153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 346.Selden C.R., Zorn M., Ratzan S.C. Health literacy. 2011 Acceso el 7 de mayo de 2011: http://www.nlm.nih.gov/archive//20061214/pubs/cbm/hliteracy.pdf. [Google Scholar]
  • 347.Dewalt D.A., Pignone M.P. The role of literacy in health and health care. Am Fam Physician. 2005;72:387–388. [PubMed] [Google Scholar]
  • 348.Easton P., Entwistle V.A., Williams B. Health in the ‘hidden population’ of people with low literacy. A systematic review of the literature. BMC Public Health. 2010;10:459. doi: 10.1186/1471-2458-10-459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 349.Powers B.J., Trinh J.V., Bosworth H.B. Can this patient read and understand written health information? JAMA. 2010;304:76–84. doi: 10.1001/jama.2010.896. [DOI] [PubMed] [Google Scholar]
  • 350.Roberts N.J., Ghiassi R., Partridge M.R. Health literacy in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:499–507. doi: 10.2147/copd.s1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 351.Davis T.C., Wolf M.S. Health literacy: implications for family medicine. Fam Med. 2004;36:595–598. [PubMed] [Google Scholar]
  • 352.Baker D.W., Parker R.M., Williams M.V., Pitkin K., Parikh N.S., Coates W. The health care experience of patients with low literacy. Arch Fam Med. 1996;5:329–334. doi: 10.1001/archfami.5.6.329. [DOI] [PubMed] [Google Scholar]
  • 353.Safeer R.S., Keenan J. Health literacy: the gap between physicians and patients. Am Fam Physician. 2005;72:463–468. [PubMed] [Google Scholar]
  • 354.Adams S.G., Smith P.K., Allan P.F., Anzueto A., Pugh J.A., Cornell J.E. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med. 2007;167:551–561. doi: 10.1001/archinte.167.6.551. [DOI] [PubMed] [Google Scholar]
  • 355.Bourbeau J., Van der Palen J. Promoting effective self-management programmes to improve COPD. Eur Respir J. 2009;33:461–463. doi: 10.1183/09031936.00001309. [DOI] [PubMed] [Google Scholar]
  • 356.Bodenheimer T., MacGregor K., Sharifi C. California Healthcare Foundation; Oakland: 2005. Helping patients manage their chronic conditions. [Google Scholar]
  • 357.Mauksch L.B., Dugdale D.C., Dodson S., Epstein R. Relationship, Communication, and Efficiency in the Medical Encounter. Arch Intern Med. 2008;168:1387–1395. doi: 10.1001/archinte.168.13.1387. [DOI] [PubMed] [Google Scholar]
  • 358.Langewitz W., Denz M., Keller A., Kiss A., Rüttimann S., Wössmer B. Spontaneous talking time at start of consultation in outpatient clinic: cohort study. Br Med J. 2002;325:682–683. doi: 10.1136/bmj.325.7366.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 359.Hanson J.L. Shared decision making. Have we missed the obvious? Arch Intern Med. 2008;168:1368–1370. doi: 10.1001/archinte.168.13.1368. [DOI] [PubMed] [Google Scholar]
  • 360.Bourbeau J., Julien M., Maltais F., Rouleau M., Beaupré A., Bégin R. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163:585–591. doi: 10.1001/archinte.163.5.585. [DOI] [PubMed] [Google Scholar]
  • 361.De Vries B., Darling-Fisher C., Thomas A.C., Belanger-Shugart E.B. Implementation and outcomes of group medical appointments in an outpatient specialty care clinic. J Am Acad Nurse Pract. 2008;20:163–169. doi: 10.1111/j.1745-7599.2007.00300.x. [DOI] [PubMed] [Google Scholar]
  • 362.Jaber R., Braksmajer A., Trilling J., Group visits for chronic illness care: models, benefits and challenges Fam Pract Manag. 2006;13:37–40. [PubMed] [Google Scholar]
  • 363.Bischoff E.W., Hamd D.H., Sedeno M., Benedetti A., Schermer T.R., Bernard S. Effects of written action plan adherence on COPD exacerbation recovery. Thorax. 2011;66:26–31. doi: 10.1136/thx.2009.127621. [DOI] [PubMed] [Google Scholar]
  • 364.Universidad de los pacientes [accedido 7 May 2011]. Disponible en: http://www.universidadpacientes.org/kitdevisitamedica/elkit/index.php?pag=descarga.
  • 365.Jovell A., Navarro Rubio M., Fernández Maldonado L., Blancafort S. Nuevo rol del paciente en el sistema sanitario. Aten Primaria. 2006;38:234–237. doi: 10.1157/13092347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 366.The Expert Patient A New Approach to Chronic Disease Managementfor the 21st Century [accedido 8 May 2011]. Disponible en: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4018578.pdf.
  • 367.González Mestre A., Fabrellas Padrés N., Agramunt Perelló M., Rodríguez Pérez E., Grifell Martín E. De paciente pasivo a paciente activo. Programa Paciente Experto del Institut Català de la Salut. Revista de Innovación Sanitaria y Atención Integrada. 2008;1(1) Article 3. [accedido 8 May 2011]. Disponible en: http://pub. bsalut.net/risai/vol1/iss1/3. [Google Scholar]
  • 368.Lorig K. Partnerships between expert patients and physicians. Lancet. 2002;359:814–815. doi: 10.1016/S0140-6736(02)07959-X. [DOI] [PubMed] [Google Scholar]
  • 369.Lorig K.R., Ritter P.L., Dost A., Plant K., Laurent D.D., McNeil I. The Expert Patients Programme online, a 1-year study of an Internet-based self-management programme for people with long-term conditions. Chronic Illn. 2008;4:247–256. doi: 10.1177/1742395308098886. [DOI] [PubMed] [Google Scholar]
  • 370.Martí M., Fabrellas N., Chicote S., Escribano V., Raventós A., Padilla N. Llamada al autocuidado. Seguimiento telefónico a enfermedades crónicas. Revista de Innovación Sanitaria y Atención Integrada. 2008;1(3) Artículo 7. [accedido 8 May 2011]. Disponible en: http://pub.bsalut.net/risai/vol1/iss3/7. [Google Scholar]
  • 371.Marshall A., Medvedev O., Antonov A. Use of a smartphone for improved selfmanagement of pulmonary rehabilitation. Int J Telemed Appl. 2008;75:30–64. doi: 10.1155/2008/753064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 372.De Toledo P., Jiménez S., Del Pozo F., Roca J., Alonso A., Hernandez C. Telemedicine experience for chronic care in COPD. IEEE Transactions on Information Technology in Biomedicine. 2006;10:567–573. doi: 10.1109/titb.2005.863877. [DOI] [PubMed] [Google Scholar]
  • 373.Torrente E., Escarrabill J., Martí T. Impacto de las redes sociales de pacientes en la práctica asistencial. Revista de Innovación Sanitaria y Atención Integrada. 2010;2(1) Article 1. [accedido 8 May 2011]. Disponible en: http://pub.bsalut.net/risai/vol2/iss1/1. [Google Scholar]
  • 374.Tapscott D., Williams D. Atlantic Books; London: 2006. Wikinomics. [Google Scholar]

Articles from Archivos De Bronconeumologia are provided here courtesy of Elsevier

RESOURCES